QualityStocksNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Highlights Two Years of Clinical Milestones Across Oncology and Rare Disease Programs
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, announced a summary of major accomplishments achieved over the past two years. The update highlights progress across multiple late-stage programs, including OT-101, now in Phase 3 for pancreatic cancer with additional applications in ARDS/COVID-19, and OXi4503, advancing from Phase 2 in AML/MDS toward pivotal Phase 3 design. Other assets include CA4P/Fosbretabulin, AL-101 for Parkinson’s disease and sexual dysfunctions, AL-102 in discovery for Alzheimer’s disease, pediatric rare disease programs with potential Priority Review Vouchers, and a nanomedicine pipeline advancing several 505(b)(2) drug candidates. CEO Dr. Vuong Trieu…
